ArticleStem cell reviews and reports2025
A Comparative Study of Mesenchymal Stem Cells from Various Sources in Endometrial Repair: the Significant Advantages of Decidual Mesenchymal Stem Cells.
Article in Stem cell reviews and reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Synergistic effects of tanshinone IIA and mesenchymal stem cells on neuroprotection, cardiovascular repair, tissue regeneration, muscle protein synthesis, and gut microbiota modulation across neurodegenerative, cardiovascular, and regenerative disease models.Frontiers in cell and developmental biology · 2026Review
- Stem cell therapy targets THBS1 to reverse endometrial fibrosis.Frontiers in cell and developmental biology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundEndometrial injury, particularly intrauterine adhesions (Asherman's syndrome), significantly compromises female fertility. Current treatments, including hysteroscopic surgery, intrauterine barriers, and oral estrogen, have limited efficacy, with postoperative pregnancy rates of 22.2-33.3%. Mesenchymal stem cells (MSCs) offer a promising alternative due to their multilineage differentiation and tissue repair capabilities. This study compared the efficacy of MSCs derived from bone marrow, umbilical cord, adipose tissue, and decidua in repairing damaged endometrium.
methodsProliferation of MSCs was assessed using the CCK8 assay. In vitro differentiation into endometrial epithelial cells was evaluated via immunofluorescence and Western blot. In vivo, a rat model of intrauterine adhesion was used to assess endometrial repair following MSC infusions.
resultsBone marrow MSCs had the highest proliferation rate, while adipose-derived MSCs had the lowest. Decidual MSCs exhibited superior differentiation into endometrial epithelial cells and the most effective in vivo repair.
conclusionsDecidual MSCs show superior efficacy in endometrial repair, highlighting their potential for treating intrauterine adhesions. Future studies should focus on clinical validation and mechanistic exploration.
Indexed as
Identifiers
40762881What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.